CRN 00808

Drug Profile

CRN 00808

Alternative Names: CRN-00808

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crinetics Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Somatostatin receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acromegaly

Most Recent Events

  • 12 Sep 2017 Preclinical trials in Acromegaly in USA (PO)
  • 10 Sep 2017 Phase-I clinical trials in Acromegaly (In volunteers) in Australia (PO, Liquid, Capsule) (NCT03276858)
  • 13 Jul 2017 Crinetic Pharmaceuticals receives SBIR grant from National Institute of Diabetes and Digestive and Kidney Diseases for CRN 00808 development in Acromegaly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top